| 产品描述: | PARP抑制剂;PARP Inhibitors;;InformationRBN012759 RBN012759 is a potent and selective inhibitor of PARP14 with IC50 of <3 nM and 5 nM for human catalytic domain and mouse catalytic domain, respectively. RBN012759 contributes to anti-tumor immune response.Targetshuman PARP14 (Cell-free assay); mouse PARP14 (Cell-free assay) <3 nM; 5 nMIn vitroRBN012759 is a sufficiently soluble, highly permeable, low efflux and potent inhibitor of human and mouse PARP14 with high PARP family selectivity. RBN012759 treatment of human primary macrophages decreases the MAR/PAR signal corresponding to PARP14 self-MARylation and stabilizes PARP14 protein in a dose-dependent manner. Treatment of primary human macrophages with RBN012759 leads to decreased IL-4 driven M2-like gene expression, suggesting that PARP14 inhibition results in a less immunosuppressive phenotype.In vivoRBN012759 has moderate clearance and oral bioavailability in mice. RBN012759 is well-tolerated in mice with repeat dosing up to 500 mg/kg BID (75-fold coverage of the PARP14 mouse). |
| 体内研究: |
RBN012759 (500 mg/kg BID;口服) 在小鼠中具有良好的耐受性,重复给药。 RBN012759 (100 mg/kg;口服) 表现出适度的口服生物利用度 (30%) 和由于中等清除率 (54 mL/min/kg) 和低稳态分布容积 (1.4 L/kg) 在小鼠体内的短血浆半衰期 (0.4 小时)。 |
| 参考文献: |
1. Schenkel L, et, al. A potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants. AACR Annual Meeting 2020. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.642 ml |
13.211 ml |
26.423 ml |
| 5 mM |
0.528 ml |
2.642 ml |
5.285 ml |
| 10 mM |
0.264 ml |
1.321 ml |
2.642 ml |
| 50 mM |
0.053 ml |
0.264 ml |
0.528 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |